Research Study Search Tool

Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?

Research & Clinical Trials > Study Search Tool > The Women Choosing Surgical Prevention (WISP) Trial

The Women Choosing Surgical Prevention (WISP) Trial

This study is open to:

Women who are at increased risk of ovarian cancer who:

  • are between age 30 and 50 years of age.
  • are premenopausal, with a documented deleterious mutation in one of the following ovarian cancer genes: BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, BARD1, MSH2, MSH6, MLH1, PMS2, or EPCAM.
  • are willing to undergo two surgical procedures (if participant chooses the ISDO arm)
  • have at least 1 fallopian tube and 1 ovary. 
This study is not open to:

Patients are excluded if they:

  • have a personal history of ovarian cancer
  • are pregnant
  • are currently being treated with Tamoxifen or Aromatase Inhibitors
The Women Choosing Surgical Prevention (WISP) Trial

Women Choosing Surgical Prevention (WISP) Trial identifier:


Quality of Life:
High Risk But No Cancer

Study Contact Information

Sites are enrolling in Chicago, IL; Boston, MA; Rochester, MN;‚Äč New York, NY; Houston, TX; Seattle, WA. For more information you can contact the study by email

About the Study

The goal of the WISP Study is to compare whether removal of fallopian tubes only, delaying removal of the ovaries can safely improve sexual functioning and menopausal symptoms compared to standard risk-reducing removal of the ovaries and fallopian tubes (also known as risk-reducing salpingo-oophorectomy or RRSO).

What the Study Entails

This is a non-randomized study. Women who participate in this study will be able to choose which type of ovarian procedure they wish to undergo: 

  • Fallopian tube removal (salpingectomy) followed later by a second surgery to remove their ovaries later.
  • Removal of the ovaries and tubes immediately. This is the current standard-of-care recommendation for women at high risk for ovarian cancer. 


Removal of the ovaries and fallopian tubes (also known as Risk-Reducing Salpingo-Oophorectomy or RRSO) is the recommended way for high-risk patients with certain types of genetic mutations to lower their risk for ovarian cancer. With RRSO the fallopian tubes and ovaries are removed at the same time and women who have not yet reached menopause may experience symptoms and long-term side effects of early-onset menopause. New research suggests that many ovarian cancers may actually begin in the fallopian tubes leading patients and researchers to wonder if they could keep the ovaries until closer to natural menopause and still lower their risk by removing the fallopian tubes (with or without one ovary) only, followed by ovarian removal several years later. 

Study Goal

The goal of this clinical research study is to compare the changes in female sexual function between patients having interval salpingectomy with delayed oophorectomy (ISDO) with those having risk-reducing salpingo-oophorectomy (RRSO) in women who carry genetic mutations. Researchers also want to learn how these surgeries affect your quality of life.

ISDO is surgery to remove the fallopian tubes first, then the ovaries are removed during a second, later surgery. Most women with genetic mutations will be encouraged to remove the ovaries around the ages of 40 to 50. The decision in timing to remove your ovaries will be made with your doctor.

You can visit the WISP website for more information.

Study Lead Investigator

Principal Investigator: Karen H. Lu, MD M.D. Anderson Cancer Center


Study Sites

The following sites are enrolling:

  • Chicago, IL
    • University of Chicago Medicine: Contact: Morgan Whipkey by phone: (773) 702-3972 or email
  • Boston, MA
    • Dana-Farber Cancer Institute: Contact: Ariana Peralta by phone: (617) 632-3743 or email
  • Rochester, MN
    • Mayo Clinic: Contact Maureen Lemens RN by phone: (507) 293-1487 or email
  • New York, NY
    • Memorial Sloan Kettering Cancer Center: Contact: Dr. Kara Long Roche/Jenny Spross, Research Study Assistant by phone: (212) 639-7043 / (646) 227-2221 
  • Houston, TX
    • MD Anderson Cancer Center: Contact: Study Coordinator for WISP by phone: (832) 750-1796 or email
  • Seattle, WA
    • University of Washington Medicine: Contact: Enna Hun by phone: (206) 616-3913 or by email

FORCE:Facing Our Risk of Cancer Empowered